NCT06989697View on ClinicalTrials.gov

Cilostazol-Ginkgo for Cognitive Function in Elderly Diabetes

PHASE3RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions
Type 2 Diabets MellitusCognitive Ability, General
Interventions
DRUG

Cilostazol / Ginko Leaf Dried Ext.

Patients will receive a light green, oval-shaped, sustained-release film-coated tablet containing a combination of cilostazol (200 mg) and ginkgo biloba extract (160 mg), administered orally once daily.

DRUG

Placebo

Patients will receive a placebo identical in taste, aroma, and formulation to the active treatment, administered orally once daily.

Trial Locations (1)

Unknown

RECRUITING

Seoul National University Bundang Hospital, Seongnam-si

All Listed Sponsors
collaborator

SK Chemicals Co., Ltd.

INDUSTRY

lead

Seoul National University Bundang Hospital

OTHER